Loading clinical trials...

Impact of Flumazenil on the Emergence Delirium | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Impact of Flumazenil on the Emergence Delirium

The Impact of Administration of Flumazenil on the Emergence Delirium in Patients Anesthetized With Remimazolam: a Prospective Randomized Single-blind Study

NCT05681377•Korea University Guro Hospital

View on ClinicalTrials.gov

Summary

Flumazenil rapidly antagonizes benzodiazepines (BZDs); it may induce agitation, seizure, or delirium, especially when applied to patients who have taken BZDs for a long time. On the contrary, it may help patients regain consciousness in a stable and calm state by appropriately reversing the central nervous system depressant effects of BZDs. In this study, we aim to investigate the impact of flumazenil on the emergence delirium in patients anesthetized with remimazolam, the short-acting BZD drug.

Eligibility

Age

19 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adult patients aged 19 years or older undergoing surgery under general anesthesia

Exclusion Criteria

•Peripheral nerve block or Neuraxial block
•Uncontrolled hypertension (HTN) (systolic blood pressure (SBP) ≥180 mmHg)
•Uncontrolled diabetes mellitus (DM) (HbA1c ≥9.0%)
•Hepatic dysfunction (Total bilirubin ≥3.0 mg/mL or Liver enzyme ≥Upper normal limit x 2.5)
•Renal dysfunction (Estimated glomerular filtration rate (eGFR) \<30 ml/min/1.73m2 or Dialysis)
•Moderate or severe chronic obstructive pulmonary disease or Respiratory failure
•Emergency
•Hepatectomy or Liver transplantation
•Intraoperative cardiopulmonary bypass (CPB) or extracorporeal membrane oxygenation (ECMO) use
•Head trauma, Increased intracranial pressure, Craniotomy
+10 more criteria

Locations (1)

Korea University Guro Hospital

Seoul, South Korea

Key Dates

Start Date

March 5, 2023

Primary Completion Date

August 11, 2023

Completion Date

August 11, 2023

Last Updated

September 6, 2023

Enrollment

ACTUAL participants

Conditions

Anesthesia, General

Interventions

Flumazenil

DRUG

Sugammadex-Induced Clenching During Neuromuscular Blockade Reversal

NCT06962007

Neuromuscular Blockade Reversal AgentPerioperative Complications+4 more

View study

COMPLETED

Predictors of Anesthesia Complications in Patients Undergoing Bariatric Surgery

NCT06981793

Bariatric SurgeryAnesthesia, General+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 6, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Impact of Flumazenil on the Emergence Delirium

Inclusion Criteria

Exclusion Criteria

Sugammadex-Induced Clenching During Neuromuscular Blockade Reversal

Predictors of Anesthesia Complications in Patients Undergoing Bariatric Surgery

Observation on Administration of Propofol at Different Titration Endpoints

Muscle Relaxants and Laryngeal Local Anesthetics for Laryngeal Mask Airway Insertion Decreasing Propofol in Elderly

The ED95 Dose of Sugammadex to Reverse Rocuronium-Induced Deep Neuromuscular Block Back to Shallow Neuromuscular Block

High Flow Nasal Cannula for Safe Apnea